• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Impact of renal function on ischemic stroke and major bleeding rates in nonvalvular atrial fibrillation patients treated with warfarin or rivaroxaban: a retrospective cohort study using real-world evidence.
CONCLUSIONS: Ischemic stroke rates were significantly lower in the overall NVAF population for rivaroxaban vs warfarin users, including patients with eCrCl below 50 mL/min. For all renal function groups, major bleeding risks were not statistically different between treatment groups. PMID: 28590785 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - June 8, 2017 Category: Research Tags: Curr Med Res Opin Source Type: research

Common clinical blood and urine biomarkers for ischemic stroke: an Estonian Electronic Health Records database study
ConclusionsWe conclude that the EHR database and the risk factors uncovered are valuable resources in screening the population for risk of IS as well as constructing disease risk scores and refining prediction models for IS by ML.
Source: European Journal of Medical Research - March 25, 2023 Category: Research Source Type: research

Safety and effectiveness of apixaban in comparison to warfarin in patients with nonvalvular atrial fibrillation: a propensity-matched analysis from Japanese administrative claims data.
CONCLUSIONS: Our observational data from clinical practice broadly confirm the safety and efficacy results of pivotal randomized controlled trials of apixaban for stroke prevention among NVAF patients. PMID: 29772946 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - May 19, 2018 Category: Research Tags: Curr Med Res Opin Source Type: research

Treatment and discharge patterns among patients hospitalized with non-valvular atrial fibrillation transitioning from the inpatient to outpatient setting.
CONCLUSIONS: Most patients hospitalized for NVAF were discharged to home support, and the majority did not have OAC treatment during hospitalization or the 30 days post-discharge. Additional investigation should be conducted on trends beyond 30 days post hospitalization and the reasons for not receiving anticoagulation therapy in patients at moderate to severe risk of stroke or systemic embolism. Helping to avoid preventable strokes is an important goal for public health. PMID: 29235900 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - December 15, 2017 Category: Research Tags: Curr Med Res Opin Source Type: research

Administrative claims data to support pragmatic clinical trial outcome ascertainment on cardiovascular health.
CONCLUSION: This study demonstrated the value of supplementing longitudinal site-based clinical studies with administrative claims data. Our results suggest that claims data together with network partner electronic health record data constitute an effective vehicle to capture patient outcomes since >30% of patients have non-fatal and fatal events outside of enrolling sites. PMID: 31081367 [PubMed - as supplied by publisher]
Source: Clinical Trials - May 12, 2019 Category: Research Authors: Ma Q, Chung H, Shambhu S, Roe M, Cziraky M, Jones WS, Haynes K Tags: Clin Trials Source Type: research

Effectiveness and Safety of Rivaroxaban Versus Warfarin in Obese Nonvalvular Atrial Fibrillation Patients: Analysis of Electronic Health Record Data.
Conclusions: Among obese NVAF patients, prescription of rivaroxaban was associated with a reduced risk of SSE and major bleeding compared to warfarin, which remained consistent across BMI classes. PMID: 32347755 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - May 1, 2020 Category: Research Tags: Curr Med Res Opin Source Type: research

Assessing the use of observational methods and real-world data to emulate ongoing randomized controlled trials
CONCLUSION: Despite challenges, observational methods and real-world data can be leveraged in certain important situations for a more timely evaluation of drug effectiveness and safety in more diverse and representative patient populations.PMID:37589143 | DOI:10.1177/17407745231193137
Source: Clinical Trials - August 17, 2023 Category: Research Authors: Joshua D Wallach Yihong Deng Eric C Polley Sanket S Dhruva Jeph Herrin Kenneth Quinto Charu Gandotra William Crown Peter Noseworthy Xiaoxi Yao Molly Moore Jeffery Timothy D Lyon Joseph S Ross Rozalina G McCoy Source Type: research